Xenon Pharmaceuticals Inc. $XENE Shares Purchased by DNB Asset Management AS

DNB Asset Management AS lifted its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 9.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 272,831 shares of the biopharmaceutical company’s stock after acquiring an additional 23,750 shares during the period. DNB Asset Management AS’s holdings in Xenon Pharmaceuticals were worth $12,228,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Wellington Management Group LLP boosted its holdings in Xenon Pharmaceuticals by 66.0% in the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after purchasing an additional 1,435,096 shares during the last quarter. Commodore Capital LP boosted its holdings in Xenon Pharmaceuticals by 30.1% in the second quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock valued at $94,682,000 after purchasing an additional 700,000 shares during the last quarter. Vestal Point Capital LP boosted its holdings in Xenon Pharmaceuticals by 53.8% in the second quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock valued at $62,600,000 after purchasing an additional 700,000 shares during the last quarter. Holocene Advisors LP boosted its holdings in Xenon Pharmaceuticals by 9.2% in the third quarter. Holocene Advisors LP now owns 1,976,553 shares of the biopharmaceutical company’s stock valued at $79,359,000 after purchasing an additional 167,078 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in Xenon Pharmaceuticals by 8.9% in the third quarter. Alliancebernstein L.P. now owns 1,654,417 shares of the biopharmaceutical company’s stock valued at $66,425,000 after purchasing an additional 135,890 shares during the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Jefferies Financial Group set a $100.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. JPMorgan Chase & Co. upped their price target on shares of Xenon Pharmaceuticals from $77.00 to $80.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Xenon Pharmaceuticals from $56.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. Morgan Stanley set a $97.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Finally, Wedbush lowered their price target on shares of Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating on the stock in a report on Monday, March 16th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Xenon Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $77.07.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, insider Andrea Difabio sold 2,607 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total value of $156,706.77. Following the completion of the transaction, the insider owned 4,893 shares in the company, valued at approximately $294,118.23. This represents a 34.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Ian Mortimer sold 270,000 shares of the company’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $60.33, for a total transaction of $16,289,100.00. Following the completion of the transaction, the chief executive officer owned 6,000 shares of the company’s stock, valued at approximately $361,980. This trade represents a 97.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 296,707 shares of company stock worth $17,845,365. Company insiders own 4.07% of the company’s stock.

Xenon Pharmaceuticals Stock Performance

Shares of Xenon Pharmaceuticals stock opened at $54.39 on Monday. The firm has a 50-day simple moving average of $56.07 and a two-hundred day simple moving average of $47.19. The company has a market cap of $5.26 billion, a P/E ratio of -11.57 and a beta of 0.65. Xenon Pharmaceuticals Inc. has a fifty-two week low of $28.19 and a fifty-two week high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.17). During the same quarter last year, the company posted ($0.83) earnings per share. Equities research analysts forecast that Xenon Pharmaceuticals Inc. will post -4.88 EPS for the current year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.